Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
NUVB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.67 - $4.16
Previous CloseN/A
Volume977.37K
Average Volume (3M)2.57M
Market Cap
$640.10M
Enterprise Value$88.52M
Total Cash (Recent Filing)$34.51M
Total Debt (Recent Filing)$3.53M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
May 20, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.25
Shares Outstanding337,678,860
10 Day Avg. Volume3,209,985
30 Day Avg. Volume2,567,892
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)81.30
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit111.35
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$10.00Price Target Upside429.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Nuvation Bio News
PremiumCompany Announcements
Nuvation Bio Reports Transformative Year in 2024---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentNuvation is developing potentially best in class drugs with clear signs of differentiation and a workable safety profile.
ManagementNuvation has an experienced management team, including a CEO who previously sold Medivation to Pfizer for $14 billion.
Regulatory ApprovalPotential FDA approval and launch expected for taletrectinib in the ROS1+ NSCLC space, which could see a significant market opportunity.
Bears Say
Competitive MarketThere is a risk of poorer-than-anticipated commercial uptake of company products, particularly taletrectinib, due to higher-than-anticipated levels of competition or other market-related factors.
Regulatory ChallengesRisks include the failure to obtain timely approval for pipeline candidates, particularly taletrectinib.
---
Ownership Overview
27.22% Insiders
13.79% Mutual Funds
20.12% Other Institutional Investors
30.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.67 and its highest was $4.16 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $640.10M.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is May 20, 2025 which is in 56 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Mar 06, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.128 by -$0.022.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -0.15.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 337,678,860 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.128. Following the earnings report the stock price went up 6.878%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
---
Nuvation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (429.10% Upside)
$10.00 (429.10% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 208.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $162.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.62%
12-Months-Change
Fundamentals
Return on Equity
-106.27%
Trailing 12-Months
Asset Growth
-13.01%
Trailing 12-Months
Company Description
Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
---
NUVB Stock 12 Month Forecast
Average Price Target
$10.00
▲(429.10% Upside)
Technical Analysis
Fate Therapeutics
―
Iovance Biotherapeutics
―
Blueprint Medicines
―
Crispr Therapeutics AG
―
Immatics
―
Best Analysts Covering NUVB
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
-0.59%
reiterated a buy rating 19 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -0.59% per trade.
---